title: Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.
abstract: Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30 % of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade (P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.
authors.affiliation: Department of Cancer Pathology, Hokkaido University, Graduate School of Medicine, Sapporo, Japan.
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Kato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishihara
authors.forename: Hiromi
authors.initials: H
authors.lastname: Mohri
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kanno
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Taichi
authors.initials: T
authors.lastname: Kimura
authors.forename: Mishie
authors.initials: M
authors.lastname: Tanino
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Terasaka
authors.forename: Shinya
authors.initials: S
authors.lastname: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D063646:Carcinogenesis / Q000235:genetics*; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D005260:Female; D015870:Gene Expression; D006651:Histocytochemistry; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D008579:Meningioma / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D014407:Tumor Cells, Cultured; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D051546:Cyclooxygenase 2